CHEK2 and ovarian carcinoma: As CHK2 has been previously shown to be associated with cisplatin sensitivity in ovarian cancer (Zhang et al, 2005), we hypothesised that the modulation of cisplatin sensitivity by knockdown of EDD expression may be an indirect effect caused by reduced EDD binding to CHK2.